The FDA will now require makers of GLP-1s like Ozempic and Zepbound to add a warning about a rare condition causing vision loss to the drugs’ labels.
Related Posts
-
FDA adds warning about rare vision loss to popular GLP-1s
The FDA will now require makers of GLP-1s like Ozempic and Zepbound to add a…
-
Nvidia shares fall after report of CEO investigation
Nvidia shares fell after reports that CEO Jensen Huang was the target of a foreign…
-
Judge denies three key motions in Lindsay Clancy case, clearing path for decision about second trial
Judge denies three key motions in the Lindsay Clancy case, moving the accused mother closer…
-
FBI probes possible homicide aboard cruise ship out of Galveston
The FBI is investigating a “suspected homicide” after a cruise ship out of Texas turned…
Leave a Reply